or Try an Advanced Search...

    ETF Components for HELX - Franklin Genomic Advancements ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    MEDP C -1.96 7.62
    TMO C -0.98 4.75
    VRTX C -0.76 4.72
    REGN D -1.75 4.59
    KRYS B -2.12 4.35
    LLY D -1.00 4.34
    DHR C -1.84 4.09
    BRKR D -1.96 3.27
    NTRA A -0.24 2.99
    AZN A 5.38 2.51
    CRL D -4.85 2.42
    CDNS D -0.21 2.35
    IONS D -1.44 2.32
    CTVA C -0.13 2.19
    A D -0.81 2.17
    RCKT F -6.47 2.14
    MRNA A -2.45 2.03
    EXAS F -7.04 1.99
    QGEN D -1.06 1.81
    BNTX F -1.57 1.71
    SRPT B 2.53 1.57
    ICLR C -3.02 1.52
    FDMT D -2.97 1.40
    ALNY F -0.06 1.33
    NTLA F -5.43 1.25
    IQV C -2.85 1.17
    VYGR F -1.98 1.14
    AZTA F -1.13 1.07
    RARE D -0.97 1.00
    RGEN D -1.31 1.00
    LH F -4.61 0.96
    TECH F -1.35 0.87
    CRSP F -3.45 0.80
    INSM D -3.45 0.79
    NBIX B -0.87 0.78
    BMY F -8.51 0.73
    LGND D -0.89 0.70
    TWST C 1.07 0.67
    BEAM F -5.01 0.66
    BIO F -0.94 0.66
    BBIO F -2.80 0.57
    CDMO D 7.17 0.57
    SDGR F -2.91 0.53
    AVTR B -1.22 0.52
    UTHR A -0.44 0.51
    DVAX F -2.19 0.49
    SLP A -2.14 0.42
    RXRX D -1.26 0.36
    ARE D -1.96 0.31
    DOCS F -1.34 0.30
    FTRE D -2.42 0.18
    VCYT F -2.11 0.14
    OLK C 2.85 0.12
    TXG F -2.25 0.11
    PACB F 1.47 0.04

    Represented by ETF Holdings

    Keywords: Biotechnology S&P 500 Biology Life Sciences Biopharmaceutical Medicine Clinical Development Acid Cancer Drug Discovery Infectious Diseases Lab Testing Amyloid Antibodies Cholesterol In Vitro Molecular Biology Nasdaq 100 Amyloidosis Asthma
    Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major Health Information Services Health Information Services Agricultural Inputs REIT - Office Semiconductor Equipment & Materials Software - Application Specialty Chemicals

    Recent News for Franklin Genomic Advancements ETF & its Holdings

    Date Stock Title
    Apr 26 BMY Q1 2024 Bristol-Myers Squibb Co Earnings Call
    Apr 25 DHR Senior Vice President - General Counsel Brian Ellis Sells 4,000 Shares of Danaher Corp (DHR)
    Apr 25 NBIX Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
    Apr 25 VRTX Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
    Apr 25 TECH Western Digital Q3 Earnings: Revenue Beat, Higher ASP, Upbeat Q4 Guidance And More
    Apr 25 TECH Students Demand Universities Sell Off Israel-Related Stocks, Hundreds Arrested In Nationwide Protests: 'Stop Investing In This Genocide'
    Apr 25 DHR Danaher Q1: The Worst Time Has Already Passed
    Apr 25 TECH Atlassian Q3 Earnings: Revenue Beat, EPS Beat, CEO Transition And More
    Apr 25 BMY Bristol Myers Squibb stock tumbles on cost-cutting initiative
    Apr 25 RARE Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
    Apr 25 BRKR Bruker Announces Date and Time of First Quarter 2024 Earnings Release and Webcast
    Apr 25 DOCS Doximity to Release Fiscal 2024 Fourth Quarter and Full Year Results on May 16, 2024
    Apr 25 BMY Bristol-Myers Squibb Stock: Gloomy Q1 Earnings Trigger Justified Sell-Off
    Apr 25 LH Laboratory Corporation of America Holdings (LH) Q1 2024 Earnings Call Transcript
    Apr 25 AZN AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'
    Apr 25 TECH 2 Semiconductor MANGO Stocks Trading Near 52-Week Lows As They Head Into Q1 Earnings
    Apr 25 BMY Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
    Apr 25 TECH Meta's Q1 Earnings: Most Analysts Support AI Strategy, While One Says 'Use Meta As A Source Of Funds,' Questions Its Long-Term Value
    Apr 25 BMY Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
    Apr 25 REGN AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
    Seeks capital appreciation by investing in innovative companies related to genomic-based technologies designed to enhance the quality of life. Provides access to companies benefitting from or facilitating the use of new research including DNA sequencing, gene editing and personalized medicine Uses bottom-up fundamental research conducted by dedicated, industry-specific analysts to identify disruptive business models at the right stage for investment Actively managed by a seasoned portfolio management team that is based in Silicon Valley and has a long history of investing in the craft of innovation
    Exchange Traded Fund ETF Biotechnology Life Sciences Biology Emerging Technologies Molecular Biology Genetics Portfolio Management Quality Of Life DNA DNA Sequencing Personalized Medicine
    Back to the Main HELX Page...